+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 12Years +
All Genders
ID07690371

Evaluating Rezpegaldesleukin Injections Compared to Placebo for Moderate-to-Severe Atopic Dermatitis in Patients Aged 12 and Older

Led by Nektar Therapeutics · Updated on 2026-10-21

510

Participants Needed

20

Research Sites

30 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating Rezpegaldesleukin as a treatment for people aged 12 years and older who have moderate to severe atopic dermatitis. This Phase 3, randomized, double-blind study compares Rezpegaldesleukin to a placebo to assess its effect on this skin condition. The overall participation lasts about 15 months. Participants will receive Rezpegaldesleukin or placebo injections during an induction period every 2 weeks. Afterward, during the maintenance period, Rezpegaldesleukin is given every 4 or 12 weeks, while placebo is given every 4 weeks. There is also an open-label escape phase where dosing frequency is decided by the investigator. Treatments are given by subcutaneous injection. During the study, participants will undergo assessments including the Investigators Global Assessment IGA score, Eczema Area and Severity Index EASI, itch and skin pain scales, sleep quality questionnaires, and asthma and nasal symptom scores. These evaluations happen at baseline, Week 6, and Week 24. Safety is monitored throughout, with adverse events recorded until about Week 56. Participants are followed for approximately 15 months in total.

CONDITIONS

Brief Title

A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis

Research Team

N

Nektar Recruitment

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here